TG Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade TG Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.
CEOMichael Sean Weiss
CEOMichael Sean Weiss
Employees338
Employees338
HeadquartersMorrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded1993
Founded1993
Employees338
Employees338
TGTX Key Statistics
Market cap6.18B
Market cap6.18B
Price-Earnings ratio151.99
Price-Earnings ratio151.99
Dividend yield—
Dividend yield—
Average volume1.53M
Average volume1.53M
High today$38.98
High today$38.98
Low today$36.50
Low today$36.50
Open price$36.97
Open price$36.97
Volume1.63M
Volume1.63M
52 Week high$46.48
52 Week high$46.48
52 Week low$16.65
52 Week low$16.65
Analyst ratings
78%
of 9 ratingsBuy
77.8%
Hold
11.1%
Sell
11.1%
People also own
Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.